Journal of Antimicrobial Chemotherapy (2002) 49, 155-160
© 2002 The British Society for Antimicrobial Chemotherapy
Antimicrobial practice |
Once–daily versus twice–daily intravenous administration of vancomycin for infections in hospitalized patients
a Recanati Centre for Medicine and Research and Clinical Pharmacology Unit, b Infectious Diseases Unit and c Microbiology Laboratory, Beilinson Campus, Petach-Tikva and Sackler Medical School, Tel-Aviv; d Infectious Diseases Unit, Chaim Sheba Medical Centre, Tel-Hashomer and Sackler Medical School, Tel-Aviv, Israel
The efficacy and toxicity of once-daily (od) versus twice-daily (bd) dosing of vancomycin was compared in 121 hospitalized patients. Eighteen patients were then withdrawn from the study. Clinical and bacteriological responses were evaluated in all patients (n = 103). Nephrotoxicity was assessed in patients who did not receive nephrotoxic agents (n = 76). Ototoxicity was assessed in patients who completed two audiograms and were not receiving ototoxic agents (n = 63). No significant difference was found between the two groups for favourable clinical response: 47/51 (92.1%) and 49/52 (94.2%) in the od and bd groups, respectively. In 34 patients vancomycin was the only effective antibiotic. Fifteen of 18 (83.3%) evaluated episodes in the od and 12/16 (75.0%) evaluated episodes in the bd group showed a favourable bacteriological response. There were no significant differences between the od and bd groups for all adverse events. Nephrotoxicity developed in 4/37 (10.8%) and 3/39 (7.7%) patients, respectively. Hearing loss developed in 1/31 (3.2%) and 5/32 (15.6%). Phlebitis occurred in 7/51 (13.7%) and 12/52 (23.0%). Red man syndrome occurred in 7/51 (13.7%) and 5/52 (9.6%) in od and bd groups, respectively. The efficacy and safety profile of od administration of vancomycin is similar to that of the customary, but less convenient, bd administration.
* Correspondence adddress. Recanati Centre for Internal Medicine and Research, Rabin Medical Centre, Beilinson Campus, Petach-Tikva, Israel 49100. Tel: +972-3-9377362; Fax: +972-3-9244663; E-mail: mgarty{at}post.tau.ac.il
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Rybak, B. Lomaestro, J. C. Rotschafer, R. Moellering Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am. J. Health Syst. Pharm., January 1, 2009; 66(1): 82 - 98. [Full Text] [PDF]
|
|
|
|
 |
|
 K. D. Leuthner, C. M. Cheung, and M. J. Rybak Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus J. Antimicrob. Chemother., August 1, 2006; 58(2): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Gemmell, D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, R. E. Warren, and on behalf of the Joint Working Party of the Britis Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK J. Antimicrob. Chemother., April 1, 2006; 57(4): 589 - 608. [Abstract] [Full Text] [PDF]
|
|